US Patent Issued to Takeda Pharmaceutical on July 15 for "Methods and compositions for treatment of hunter syndrome comprising iduronate-2-sulfatase" (Massachusetts Inventor)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,359,178, issued on July 15, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Methods and compositions for treatment of hunter syndrome comprising iduronate-2-sulfatase" was invented by Dave Nichols (Lexington, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as...